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https://doi.org/10.1016/j.xcrm.2021.100229SUMMARYThe impact of secondary bacterial infections (superinfections) in coronavirus disease 2019 (COVID-19) is not
well understood. In this prospective, monocentric cohort study, we aim to investigate the impact of
superinfections in COVID-19 patients with acute respiratory distress syndrome. Patients are assessed for
concomitant microbial infections by longitudinal analysis of tracheobronchial secretions, bronchoalveolar
lavages, and blood cultures. In 45 critically ill patients, we identify 19 patients with superinfections
(42.2%). Superinfections are detected on day 10 after intensive care admission. The proportion of partici-
pants alive and off invasive mechanical ventilation at study day 28 (ventilator-free days [VFDs] at 28 days)
is substantially lower in patients with superinfection (subhazard ratio 0.37; 95% confidence interval [CI]
0.15–0.90; p = 0.028). Patients with pulmonary superinfections have a higher incidence of bacteremia, virus
reactivations, yeast colonization, and required intensive care treatment for a longer time. Superinfections are
frequent and associated with reduced VFDs at 28 days despite a high rate of empirical antibiotic therapy.INTRODUCTION
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) has evolved as the most relevant pandemic of modern history,
challenging health care systems all over the world. The clinical
characteristics of coronavirus disease 2019 (COVID-19) patients
have been thoroughly described in recent studies.1–5 The triggers
for acute respiratory distress syndrome (ARDS) in COVID-19 are
virus initiated, subsequently leading to inflammation-mediated
lung damage and endotheliitis.5 Although primarily a viral disease,
antibiotics are empirically used in over 70% of cases in addition to
experimental antiviral and immunomodulatory treatments.1,4–7
Secondary bacterial and/or fungal infections are a well-described
phenomenon in viral illnesses, such as influenza, and are associ-
ated with increasedmorbidity and mortality in viral ARDS, as illus-
trated during previous pandemics.8 Secondary bacterial infections
are typically referred to as superinfections, whereas co-infection is
mainly used to describe simultaneous virus infection. Both co- and
superinfections have been described in COVID-19 patients.6,9
Data regarding bacterial superinfections in COVID-19 pneumonia
are limited and still emerging.10,11 A recent systematic review has
concluded that the rate of bacterial/fungal superinfections is low,This is an open access article under the CC BY-Narguing against the frequent use of broad-spectrum antimicrobials
in patients with COVID-19.11,12 However, COVID-19-associated
pulmonary aspergillosis (CAPA) has been reported in several
cohorts of critically ill patients.13,14 Still, there is a lack of knowl-
edge about the frequency and significance of bacterial, fungal,
and viral concomitant infections in critically ill COVID-19
patients.12 Additionally, in most studies performed so far, no
thorough and systematic sampling for concomitant infections
was performed. The high mortality in severely ill COVID-19
patients is thought to beat least in part due to secondary infections
in addition to viral replication in the lower respiratory tract leading
to severe lung injury and ARDS.6,15,16
Superinfection seems to represent a major risk factor for
mortality in COVID-19 patients.7,17–19 However, the risk of
superinfection in mechanically ventilated patients with severe
COVID-19 remains poorly described.
Currently, the diagnostic and treatment approach for superin-
fections remains unclear and the classical criteria for the detection
of superinfections are often of limited use in COVID-19 patients.
Clinical symptoms are an expression of the underlying disease
of COVID-19 and cannot be used to reliably distinguish between
patients presenting with or without relevant superinfections. ForCell Reports Medicine 2, 100229, April 20, 2021 ª 2021 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1. Baseline characteristics and study population
Overall (N = 45)
No bacterial
superinfection (n = 26)
Bacterial superinfection
(n = 19) p value
Baseline characteristics
Age (years) 60 (54–69) 61.5 (54–71) 59 (54–69) 0.654
Male sex (n/%) 35 (77.8%) 19 (73.1%) 16 (84.2%) 0.375
Weight (kg) 83 (75–99) 80 (72.5–90) 92 (78–100) 0.049
Height (cm) 175 (165–182) 172 (160–180) 176 (169–185) 0.112
Body mass index (kg/m2) 27.8 (25.7–31.6) 27.5 (25.6–30.6) 27.8 (26.8–35) 0.346
Comorbidity and other clinical conditions
Myocardial infarction/ischemic
heart disease
6 (13.3%) 5 (19.2%) 1 (5.3%) 0.222
Arterial hypertension 26 (57.8%) 16 (61.5%) 10 (52.6%) 0.550
Chronic kidney disease 12 (26.7%) 10 (38.5%) 2 (10.5%) 0.047
Dialysis 1 (2.2%) 1 (3.8%) 0 (0%) 0.999
Diabetes, no insulin therapy 5 (11.1%) 3 (11.5%) 2 (10.5%) 0.999
Diabetes, insulin therapy 14 (31.1%) 7 (26.9%) 7 (36.8%) 0.528
Asthma 1 (2.2%) 1 (3.8%) 0 (0%) 0.999
Chronic obstructive pulmonary disease
(COPD)
5 (11.1%) 4 (15.4%) 1 (5.3%) 0.378
Renal or liver transplantation 5 (11.1%) 4 (15.4%) 1 (5.3%) 0.378
Immunosuppression 7 (15.6%) 5 (19.2%) 2 (10.5%) 0.222
Cancer 4 (8.9%) 2 (7.7%) 2 (10.5%) 0.999
Smoking 14 (31.1%) 7 (26.9%) 7 (36.8%) 0.625
Alcohol abuse 1 (2.2%) 0 (0%) 1 (5.3%) 0.999
Drug abuse 0 (0%) 0 (0%) 0 (0%) 1.000
Medical therapy before admission
Statin 10 (22.7%) 6 (24%) 4 (21.1%) 0.999
Angiotensin-converting enzyme (ACE)
inhibitor
7 (15.9%) 4 (16%) 3 (15.8%) 0.999
Scores/index
Sepsis-related organ failure assessment
score (SOFA)
8 (5–10) 8 (3–10) 9 (7–10) 0.480
Simplified acute physiology score (SAPS) II 36 (25–50) 32.5 (24–50) 42 (28–51) 0.275
Lowest PaO2/FiO2 ratio at admission 122 (94–177) 129 (97–200) 108 (85–163.5) 0.228
Organ failure during ICU stay
Acute kidney injury 27 (60%) 15 (57.7%) 12 (63.2%) 0.712
Dialysis 18 (40%) 9 (34.6%) 9 (47.4%) 0.388
Invasive mechanical ventilation 40 (88.9%) 21 (80.8%) 19 (100%) 0.043
Extracorporeal life support (ECLS) 8 (17.8%) 3 (11.5%) 5 (26.3%) 0.253
Rescue therapies
Prone position 28 (62.2%) 11 (42.3%) 17 (89.5%) 0.001
Inhaled nitric oxide (iNO) 11 (24.4%) 5 (19.2%) 6 (31.6%) 0.341
Tracheotomy 20 (44.4%) 6 (23.1%) 14 (73.7%) 0.001
Timing (days)
Time to ICU admission 2 (1–6) 2 (1–6) 3 (1–6) 0.636
Duration prone position 6 (1–10) 1.5 (1–7) 6 (4–10) 0.022
Duration iNO therapy 3 (1–6) 1 (1–3) 4.5 (1–22) 0.349
Duration intubation to tracheotomy 20 (10–33) 10.5 (9–21) 27 (15–33) 0.114
(Continued on next page)
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Overall (N = 45)
No bacterial
superinfection (n = 26)
Bacterial superinfection
(n = 19) p value
Laboratory values at admission
White blood cell (WBC) count (G/L) 7.7 (5.7–10.7) 7.5 (5.7–10) 8 (5.3–13.4) 0.515
Hemoglobin (gr/L) 118.5 (101.5–133) 117 (107–132) 126 (98–134) 0.896
Hematocrit (%) 0.4 (0.3–0.4) 0.4 (0.3–0.4) 0.4 (0.3–0.4) 0.619
Platelet count (G/L) 199 (169.5–272) 200 (177–271) 190 (154–297) 0.776
Alanine transaminase (ALT) (U/L) 42.5 (25.5–65.5) 31 (24–60) 56 (33–72) 0.008
Lactate dehydrogenase (LDH) (U/L) 676 (527–842.5) 619 (471–742) 772 (626–876) 0.144
Alkaline phosphatase (U/L) 74.5 (53.5–103.5) 77.5 (56–108) 61 (53–98) 0.308
Urea (mmol/L) 6 (4.3–10.3) 6.2 (4.1–7.9) 6 (4.4–12.2) 0.651
Creatinine (mmol/L) 92.5 (67–138.5) 95 (70–128) 91 (57–149) 0.387
Serum sodium (mmol/L) 138 (134–141) 137 (135–140) 141 (134–146) 0.203
Serum potassium (mmol/L) 3.9 (3.7–4.5) 4.1 (3.7–4.4) 3.8 (3.5–4.7) 0.601
C-reactive protein (CRP) (mg/L) 168.5 (83.5–276.5) 124 (62–238) 255 (102–301) 0.034
Procalcitonin (PCT) (mcg/L) 0.3 (0.2–1.2) 0.2 (0.1–1.7) 0.4 (0.2–1.2) 0.060
Interleukin-6 (IL-6) (ng/L) 127 (71.2–454) 122 (84–697) 127 (62.7–263) 0.554
COVID-19 targeted drug therapy and antimicrobials
Steroids 21 (46.7%) 8 (30.8%) 13 (68.4%) 0.012
Hydroxychloroquine 27 (61.4%) 13 (52%) 14 (73.7%) 0.143
Lopinavir/ritonavir 7 (15.9%) 4 (16%) 3 (15.8%) 0.999
Remdesivir 8 (18.2%) 4 (16%) 4 (21.1%) 0.704
Tocilizumab 2 (4.7%) 2 (8.3%) 0 (0%) 0.501
Empiric antimicrobial therapy 40 (8,839%) 22 (88%) 18 (94.7%) 0.441
Sample size overall
TBS 433 114 319
BAL 35 12 23
Blood cultures 455 152 303
Demographic and clinical characteristics as well as risk factors of COVID-19 patients stratified according to presence or absence of pulmonary rele-
vant pathogens in tracheobronchial secretions (TBSs) and bronchioalveolar lavages (BALs) reflecting superinfection. The data are presented as me-
dian (interquartile range (IQR)) or number and percentage (%). The two groups were compared using chi-square test/Fisher exact or theMann-Whitney
test as appropriate.
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OPEN ACCESSthis reason, several authors have argued in favor of an empirical
antibiotic treatment with a focus on streptococci and staphylo-
cocci in severe courses.16 Other opinion leaders recommend
(longitudinal) sampling of severely ill patients for early detection
and treatment during the entire course of the disease.6,20
Rapid diagnosis of co- and superinfections may not only help
to improve survival but would also allow targeted antimicrobial
therapy, improving antimicrobial stewardship throughout the
course of the pandemic.20,21
The aimof our studywas to assess the burden of superinfections
and the association with clinical outcomes in critically ill patients
with COVID-19 ARDS (CARDS) in a tertiary care intensive care
unit (ICU) with highly regulated antibiotic prescription.
RESULTS
Cohort characteristics
A total of 48 critically ill COVID-19 patients with ARDS were
screened in the ICUat theUniversityHospital ZurichbetweenApril
and June 2020. Three patients had to be excluded from the anal-ysis because patients or relatives denied informed consent (Fig-
ure S1). 45 patients with a median age of 60 (54–69) years were
included in this study. Most of them were male (35/45; 77.8%).
Of the 45 patients, 19 (42.2%) were diagnosed with a superinfec-
tion. The median of ventilation duration was 15 days and length of
ICU stay was 14 days overall. The median length of hospital stay
was 24 days. Baseline characteristics are summarized in Table 1.
In general, both groups of patients with and without superinfec-
tions were similar with regards to demographics and clinical char-
acteristics. In particular, there were no differences in the severity
of the disease and organ dysfunction as assessed by simplified
acute physiology score (SAPS) II and sepsis-related organ failure
assessment score (SOFA). Intensive care rescue therapies, such
as prone position (42% versus 90%) and tracheotomy (23%
versus 74%), were required more frequently and/or for longer
periods in the superinfection group (Table 1).
Microbiological sampling and superinfections
Overall, 433 tracheobronchial secretions (TBSs), 35 broncho-
alveolar lavages (BALs) samples, and 455 blood culture pairsCell Reports Medicine 2, 100229, April 20, 2021 3
Table 2. Clinical outcomes and microorganisms detected
No bacterial superinfection (n = 26) Bacterial superinfection (n = 19) p value
Outcomes and superinfection data
Duration of ventilation (days) 8 (5.9–15.1) 37 (22.2–43.7) <0.001
Length of ICU stay (days) 9 (7.0–14.9) 39 (28.5–57.0) <0.001
Length of hospital stay (days) 17 (14.4–26.4) 44 (34.2–63.3) <0.001
Patients died 6 (23.1%) 4 (21.1%) 0.999
Patients with bacterial respiratory
superinfection
0 (0%) 19 (100%)
Patients with superinfection
detected in BAL
0 (0%) 6 (31.6%)
Patients with bloodstream infection 2 (7.7%) 9 (47.4%) 0.004
Patients with Aspergillus detection 2 (7.7%) 3 (15.8%) 0.636
Patients with yeast colonization 12 (46.2%) 17 (89.5%) 0.004
Patients with multidrug resistant (MDR)
pathogens
0 (0%) 10 (52.6%) <0.001
Causative microorganisms
Microbiology of superinfections
Overall pathogen detection in TBS/BALa 83 375
Relevant pulmonary pathogen
detection in TBS/BALa
0 (0%) 169 (45.1%)
Citrobacter freundii, koseri 0 (0%) 11 (2.9%)
Enterobacter cloacae 0 (0%) 14 (3.7%)
Escherichia coli 0 (0%) 2 (0.5%)
Klebsiella aerogenes 0 (0%) 7 (1.9%)
Klebsiella pneumoniae 0 (0%) 27 (7.2%)
Legionella pneumophila 0 (0%) 2 (0.5%)
Pseudomonas aeruginosa 0 (0%) 64 (17.1%)
Acinetobacter spp. 0 (0%) 2 (0.5%)
Burkholderia cepacia 0 (0%) 30 (8.0%)
Morganella morganii 0 (0%) 3 (0.8%)
Streptococcus pneumoniae 0 (0%) 2 (0.5%)
Streptococcus anginosus 0 (0%) 3 (0.8%)
Staphylococcus aureus 0 (0%) 2 (0.5%)
Microbiology of bloodstream infections
Overall 2/152 (1.3%) 12/303 (4.0%)
Citrobacter spp. 0 (0%) 2 (16.7%)
Enterococcus faecalis and E. faecium 1 (50%) 6 (50%)
Klebsiella aerogenes 0 (0%) 1 (8.3%)
Klebsiella pneumoniae 0 (0%) 1 (8.3%)
Moraxella spp. 1 (50%) 0 (0%)
Candida glabrata 0 (0%) 1 (8.3%)
Pseudomonas aeruginosa 0 (0%) 1 (8.3%)
Viral detection
Overall 2 9
Influenza A virus 0 (0%) 1 (11.1%)
Influenza B virus 0 (0%) 0 (0%)
Respiratory viruses, multiplex PCRb (n = 34) 0 (0%) 0 (0%)
(Continued on next page)
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No bacterial superinfection (n = 26) Bacterial superinfection (n = 19) p value
Herpes simplex virus type 1 (HSV-1) (PCR in
blood)
0 (0%) 5 (55.5%)
Herpes simplex virus type 2 (HSV-2) (PCR in
blood)
0 (0%) 0 (0%)
Human herpesvirus 6 (HHV-6) (PCR in
blood)
0 (0%) 2 (22.2%)
Cytomegalovirus (CMV) (PCR in blood) 1 (50%) 0 (0%)
Epstein-Barr virus (EBV) (PCR in blood) 1 (50%) 1 (11.1%)
The data are presented as median (95% confidence interval [CI] of median) or number and percentage (%). The two groups were compared using
chi-square test/Fisher exact or the Mann-Whitney test as appropriate.
aOverall detected microorganisms, including repetitive detection in the same patient
bMultiplex PCR assay for respiratory syncytial virus (RSV) A/B; influenza A/B virus; adenovirus; coronaviruses 229E, HKU1, NL63, and OC43; human
bocavirus; human metapneumovirus (hMPV); rhino/enterovirus; and parainfluenza virus 1-4
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The range of respiratory samples per patient was 1–36 with a
median of 6 per patient.
In nineteen patients (42.2%), at least one clinically relevant
bacterium or fungus was detected in TBSs/BALs during the
study period, whereas in 26 patients (57.8%), no relevant
microorganisms were detected in TBSs/BALs.
A total of 342 TBSs/BALs were collected in the superinfection
group, and 169 pulmonary relevant microorganisms were de-
tected in these samples. Only in two cases, results did not match
between BALs and TBSs. TBSs became negative for detected
pathogens within a median of 12 days. Despite high frequency
of positive TBSs, blood cultures showed only seven different
bacterial species in 14 positive blood culture pairs (Table 2).
In the group without superinfections, 83/114 TBS samples
showed growth but without recovery of clinically relevant lung
pathogens. Candida albicans was the most frequently isolated
non-relevant organism. In the 12 BAL samples, there was also
no evidence of pulmonary relevant microorganisms. However,
bacteremia was detected twice in a total of 152 blood culture
pairs (Table 2).
The detection time points of pulmonary relevant and non-rele-
vant microorganisms are depicted in Figures 1 and S2, respec-
tively. On average, relevant pulmonary pathogens were detected
on day 10 after ICU admission and reflect the hospital-acquired
pneumonia (HAP)/ventilator-associated pneumonia (VAP) spec-
trum (Figure 1A). Non-relevant pulmonary pathogens22 were de-
tected on average on day 3 post-ICU admission (Figure S2). The
most frequently isolated bacteria per patient were Enterococcus
spp. (15/45), Enterobacter/Citrobacter (8/45), and Klebsiella
spp. (7/45). Additionally, Streptococcus pneumoniae (2/45),
Streptococcus anginosus (3/45), Escherichia coli (2/45), Entero-
bacter spp. (6/45), Citrobacter spp. (3/45), Pseudomonas
aeruginosa (6/45), Burkholderia cepacia (2/45), and coagulase-
negative staphylococci (13/45) were found.
Empirical antimicrobial therapy was given to 40/45 (88.9%)
patients, antifungal therapy to 10/45 (22.2%) patients, and anti-
viral therapy to treat concomitant viral infections to 9/45 (20%)
patients. Figures 1B and 1C summarize the antibiotic treatment
received by the patients.In ten patients (22.2%), multi-drug-resistant (MDR)
bacteria (Pseudomonas aeruginosa, Enterobacter cloacae, and
Burkholderia cepacia) were detected.
Serumreactivationofherpessimplex type1and2 (HSV-1and-2)
was detected in 5 out of 45 patients. Human herpes virus 6 (HHV-6)
was detected twice, cytomegalovirus (CMV) reactivation occurred
once, and Epstein-Barr virus (EBV) reactivation occurred twice.
One patient had a co-infection with influenza A virus (Table 2).
Furthermore, colonizations with fungi were detected, and the
isolated organisms included Candida spp. (29/45 patients),
non-Candida yeast (21/45 patients), and Aspergillus spp. (5/45
patients). A detailed overview of relevant respiratory pathogens
detected in TBSs/BALs and blood cultures is shown in Table 2.
Colonizing microorganisms not considered as being relevant
pulmonary pathogens are depicted in Figure S2.
Proportion of participants alive and off invasive
mechanical ventilation at study day 28
(ventilator-free days at 28 days)
COVID-19 patients with pulmonary superinfections had substan-
tially lower ventilator-free days (VFDs) at 28 days than those
without superinfections (Figure 2), with a subhazard ratio of
0.37 (95% confidence interval 0.15–0.90; p = 0.028).
Secondary outcomes
Patients with superinfections detected in respiratory specimens
were ventilated for significantly longer time periods (8 versus
37 days; p < 0.001) and had a significantly longer duration of
stay in the ICU (9 versus 39 days; p < 0.001) and overall hospital-
ization time (17 versus 44 days; p < 0.001) as compared to
patients without superinfections (Table 2).
Further outcomes
Patients with pulmonary superinfections had significantly more
bacteremia (p = 0.004), virus co-infections/reactivations other
than SARS-CoV-2 (p = 0.001), colonization with yeasts (p =
0.004), and infections with MDR pathogens (p < 0.001; Table 2).
Longitudinal laboratory inflammation parameters (leukocytes,
C-reactive protein [CRP], procalcitonin [PCT], and neutrophil/




Figure 1. Spectrum and isolation time points in
TBSs and BALs reflect hospital-acquired pneu-
monia (HAP)/ventilator-associated pneumonia
(VAP) spectrum
(A) First detection time points of the most frequently
cultured respiratory pathogens censored at 42 days
(detection of Acinetobacter baumannii at day 77 and
A. bereziniae at day 66). The n refers to the number of pa-
tients with a first detection of the respective pathogen. A
total of 468 respiratory specimens from 45 patients were
analyzed. Only the first detection event of a relevant respi-
ratory pathogen in a given patient is reported.
(B) Antibiotics used for treatment of superinfections.
(C) Empiric antibiotic therapy used during first course of
antibiotic treatment (before or at admission onto ICU).
See also Figures S1 and S2.
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Figure 2. Proportion of participants alive
and off invasive mechanical ventilation at
study day 28 (ventilator-free days [VFDs] at
28 days)
Cumulative incidence curves for proportion of
participants alive and off invasive mechanical
ventilation at study day 28 (VFDs at 28 days). Only
patients receiving invasive mechanical ventilation
(N = 40) were included in this analysis. See also
Figure S3 and Table S1.
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OPEN ACCESSTable S1. Only for CRP, the mixed-model evaluation showed a
significant difference between the groups with increased CRP
in the superinfection group (p < 0.001), whereas for leucocytes,
there was a significant increase in numbers over time in both
groups (Figure S3).
DISCUSSION
In this prospective cohort study of critically ill, ventilated COVID-19
patients, the presence of superinfection was associated with
extended ventilation times, increased duration of intensive care
and hospitalization, and increased need for intensive-care rescue
therapies, such as proning and steroid use. Bacterial
superinfections were detected in 42.2% of patients in our
cohort, which is slightly higher than reported in previous
studies.1,2,5,6,15,16,23 This discrepancy with other studies might be
mainly due to the nature of our cohort consisting of severely ill pa-
tients with CARDS. In addition, differing from other studies, sam-
pling was prospectively and repetitively scheduled and not only
performed at admission as in other studies, which may account
for underreporting of superinfections. Regional differences can
also play an important role in bacterial superinfections and spec-
trum of resistance. This could explain in part the increased rate
of superinfections compared to previous literature.11,24,25
Although some studies have concluded that bacterial
superinfections do not play a major role in disease severity and
treatment choices, the results of the present study challenge
the generalizability to severely ill CARDS patients.6,11 In our
cohort, isolation of relevant respiratory bacteria was associated
with more-severe COVID-19 disease courses with significantly
longer duration of invasive mechanical ventilation and prolonged
ICU and hospital stays. Compared to other studies investigating
the role of superinfection in COVID-19, duration of ICU stay and
length of ventilation was high, reflecting the disease severity of
patients included in this study.7,11 Additionally, data on theCell Reduration of ventilation and ICU stay are
often missing in other studies, making
comparisons difficult.4,11,15,21,26 Further-
more, due to the comparatively high
SOFA score upon admission but moder-
ate mortality, as in our cohort, long-term
ICU-treatment complications, such as
nosocomial infections, become more
frequent.
Relevant respiratory bacteria were iso-
lated on average on day 10 after ICUadmission in our cohort, suggestingmainly nosocomial infections.
Incontrast tobacterial superinfectionsobserved in influenzapneu-
monia, COVID-19 superinfections with Gram-positive bacteria,
such as pneumococci or staphylococci, were rare in this study. It
has to be mentioned that, in critically ill influenza patients, also in-
fectionswithGram-negative bacteria (such asP. aeruginosa) have
been reported.27 Similar observations were made for Middle East
respiratory syndrome coronavirus (MERS-CoV)- and SARS-CoV-
1-associated superinfections.28–30 In this study, mainly Gram-
negative pathogens, such as Pseudomonas and Enterobacteri-
aceae, including MDR bacteria, were isolated, which is in line
with previous reported studies.11
Based on the findings that pulmonary bacterial superinfec-
tions seem to be mostly nosocomial and were associated with
receipt of empiric broad-spectrum antibiotic therapy, use of
antimicrobials may be more appropriately guided by the detec-
tion of pathogenic bacteria in longitudinal, high-quality respira-
tory samples. Patients could only be treated if pathogenic bacte-
ria were detected in longitudinal samplings in line with
antimicrobial stewardship interventions.12,26 Future prospective,
randomized trials to investigate the efficacy of targeted
antimicrobial therapy should be conducted to define best prac-
tice regarding prevention and treatment of bacterial superinfec-
tions in COVD-19. The isolation of mainly Gram-negative rods,
including MDR, led to the use of third-line antibiotics, such as
tigecycline, ceftazidime/avibactam, or ceftolozane/tazobactam,
after initial empirical therapy of nosocomial pneumonia (Figure 1).
It is important to consider the short- and long-term
consequences that the use of antimicrobials, especially broad-
spectrum, may have on drug resistance. A worrisome potential
consequence of the COVID-19 pandemic might be the long-
term spread of antimicrobial resistance (AMR) due to increased
exposure of patients to antimicrobial agents that may have
been used inappropriately.31 In this framework, employment of
standardized longitudinal screening with early detection andports Medicine 2, 100229, April 20, 2021 7
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apy could minimize the use of broad-spectrum, second- and
third-line antibiotics, thus reducing AMR.
The high rate of yeast detection might be associated with the
widespread use of broad-spectrum empirical antimicrobial ther-
apy.32 Invasive aspergillosis was not detected by standard
methods. However, molecular detection methods might be an
important tool in future studies.33,34 So far, only few studies
have investigated fungal superinfections in COVID-19
patients.13–15,17,35–37 The significance of viral reactivation re-
mains unclear.11 In our study, reactivations of HSV-1 and HHV-
6 in the serum occurred in patients with bacterial
superinfections. These findings support the hypothesis that
superinfections associated with increased COVID-19 disease
severity might enhance susceptibility to viral reactivations.
Further studies with higher participant numbers should clarify
the significance of this finding.
Prone positioning was more frequently performed in patients
with superinfections. However, as patients received continuous
subglottic suctioning, we believe that reflux during proning
should not be an explanation for the observed superinfection
differences. Rather, proning might reflect disease severity in
the superinfection group. No selective digestive decontamina-
tion was performed.
In line with previous studies, conventional clinical laboratory
tests, such as leukocytes, PCT, and neutrophil/lymphocyte ratio
progressions, were not associated with pulmonary superinfec-
tions and therefore do not seem very useful for the detection of
bacterial superinfections in COVID-19 patients on mechanical
ventilation. Although CRP values differed significantly, the wide
range observed in both groups did not allow the identification
of a threshold value that clearly distinguishes patients with
superinfection. This complicates the diagnosis of bacterial
superinfections and emphasizes the importance of longitudinal
microbiological diagnostics.
Advantages of this study are the prospective longitudinal
monitoring of respiratory materials with concomitant recording
of demographic data, microbiological evaluations, and antimi-
crobial therapy in a tertiary care center in a high-resource setting
that did not experience health-care shortage during the first
pandemic wave. Furthermore, this study used strict definitions
for relevant respiratory pathogens. The diagnosis of superinfec-
tions was performed prospectively based on longitudinal
sampling comprising detection of not only bacterial but also viral
and fungal agents.
In summary, the detection of bacterial pulmonary superinfec-
tion was associated with a more-severe disease course in
COVID-19 patients, especially a lower likelihood of being alive
and off invasive mechanical ventilation at study day 28 (VFDs
at 28 days). Future trials should investigate the effect of tailored
antimicrobial therapy on outcome, antibiotic resistance, and
drug use based on longitudinal assessment of respiratory tract
cultures.
Limitations of study
Limitations of the study are the single-center design, small num-
ber of patients, and the high number of patients with empirical
broad-spectrum antibiotic therapy (>90% of cases) at admis-8 Cell Reports Medicine 2, 100229, April 20, 2021sion. Another limitation is the lack of a uniform, internationally
valid definition of a bacterial infection of the lower respiratory
tract and the inclusion of five patients that did not end up needing
mechanical ventilation. However, patients not on mechanical
ventilation were not included in the analysis of the primary
outcome. Finally, as with all observational studies, causality
cannot be inferred from reported associations.STAR+METHODS
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(philipp.buehler@usz.ch) or Silvio D. Brugger (silvio.brugger@usz.ch).
Materials availability
This study did not generate new unique materials.
Data and code availability
The data and analysis scripts used in this study are available upon request to the Lead author.
No new code was generated.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Study design, ethics and population
The study was conducted as part of the MicrobiotaCOVID cohort study, a single-center, prospective observational study conducted
at the Institute of Intensive Care Medicine of the University Hospital Zurich (Zurich, Switzerland) registered at clinicaltrials.gov
(ClinicalTrials.gov Identifier: NCT04410263). The study was approved by the Local Ethics Committee of the Canton of Zurich,
Switzerland (Kantonale Ethikkommission Zurich BASEC ID 2020 - 00646).
Patients with confirmed SARS-CoV-2 infection and CARDS requiring ICU support and mainly invasive mechanical ventilation
hospitalized between April 2020 and June 2020 during the first COVID-19 wave in Switzerland were eligible.
Inclusion criteria were age > 18 years, SARS-CoV-2 infection as determined by real-time reverse transcriptase-polymerase chain
reaction (RT-PCR) positivity of nasopharyngeal and/or pharyngeal swabs, TBS or BAL and hospitalization in the ICU for moderate or
severe ARDS according to the Berlin criteria38.
Exclusion criteria were patients or relatives denying informed consent and patients still being treated in the ICU when the study
period ended.
Study outcomes
The primary outcome was proportion of participants alive and off invasive mechanical ventilation at study day 28, i.e., ventilator-free
days (VFDs) at 28 days39. Patients not on mechanical ventilation were excluded for the primary outcome analysis. Secondary out-
comes were length of hospital stay, ICU stay and duration of mechanical ventilation. Further outcomes included the associationCell Reports Medicine 2, 100229, April 20, 2021 e1
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OPEN ACCESSof pulmonary superinfection and bacteraemia, other virus co-infections/reactivations, colonization with yeast, bacterial infections
with multidrug resistance (MDR), and longitudinal laboratory inflammation parameters.
METHOD DETAILS
Sample collection, processing and testing
If the respiratory situation, as assessed by the ICU attending physician in charge, allowed bronchoscopy, BAL (10ml of saline) was
collected by the ICU personnel upon ICU admission and during the later course of the disease. TBS was collected from each venti-
lated patient at least on day 0 (i.e., upon ICU admission), day 1, day 2, day 3, day 5 and henceforth every 5 days. If the clinical situation
did not allow TBS collection, no sampling was performed.
Samples were processed at the Institute for Medical Microbiology and at the Institute for Medical Virology of the University of
Zurich. Standard clinical microbiology techniques were used for culturing, isolation and identification of bacterial and fungal
microorganisms as previously described40. SARS-CoV-2 was detected by real-time RT-PCR as previously described41. Aspergillus
spp. was primarily identified in culture of TBS and BAL and also Galactomannan screening was performed in selected patients at
physician’s discretion.
At admission, multiplex PCR for respiratory syncytial virus (RSV) A/B, influenza A/B virus, adenovirus, coronaviruses 229E, HKU1,
NL63 andOC43, human bocavirus, humanmetapneumovirus (hMPV), rhino/enterovirus and parainfluenzavirus 1-4 was performed in
nasopharyngeal swabs. Multiplex PCR for the detection of atypical respiratory bacteria (Legionella pneumophila, Chlamydophilia
spp., Bordetella spp. and Mycoplasma spp.) was performed on pharyngeal swabs at ICU admission.
Moreover, we assessed serum detection and viral load of the following viruses: herpesviruses type 1 and 2 (HSV-1 and 2),
Cytomegalovirus (CMV), Epstein–Barr virus (EBV) and human herpesvirus 6 (HHV-6). Additional virus diagnostics, blood and urine
cultures were initiated by the treating physicians according to the clinical situation.
Data collection and covariates
Clinical and laboratory data were obtained from electronic health records and included demographics, comorbidities / risk factors,
medication, ICU scores, laboratory values, organ failure, need for invasive ventilation, need for extracorporeal life support (ECLS),
rescue therapies, length of ICU/hospital stay, COVID-19 targeted experimental therapy (steroids, hydroxychloroquine, lopinavir/
ritonavir, remdesivir, tocilizumab) and empiric antibiotic therapy.
Daily measurements of inflammatory parameters C-reactive protein and procalcitonin (CRP/PCT), leukocyte count and the
neutrophil/lymphocyte ratio were routinely performed over the first 16 days after ICU admission.
Definition of superinfection
A multidisciplinary panel of ICU and infectious diseases consultants (unrelated to the study group) assessed the clinical status of the
patients on a daily basis. Superinfection was diagnosed according to the panel’s judgement of clinical deterioration and routine
laboratory assessment as well as microbiological results. In more detail, the isolation of microorganisms from respiratory specimen
cultures (TBS and/or BAL) regarded as clinically relevant by the panel was used as antimicrobial treatment guidance and the first
specimen without pathogen growth was considered as the end of an episode in concordance with the clinical course. In case of
isolation of more than one respiratory pathogen (i.e., in the bacterial and/or fungal analysis sample) in a given respiratory sample
all were included in this study.
Organismswith low pathogenicity for lung infections such as Enterococcus spp.,Candida spp., coagulase-negative staphylococci
and non-pneumococcal streptococci were reported but not considered a relevant clinical pathogen of the airways in accordancewith
the literature42.
Detection of the HSV-1 and 2 as well as CMV, EBV, HHV-6 in blood were also reported but were considered reactivations. Viral
co-infections/reactivationswere only diagnosed if clinical signs of tracheitis or pathological signs of viral co-infection in cytologywere
observed.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analyses
Due to the unknown rate of concomitant infections in severely ill COVID-19 patients a power calculation was not feasible.
Comparisons of population characteristics were performed usingMann-Whitney U tests and the Chi-square/Fisher exact test for cat-
egorical variables, as appropriate. For longitudinal analysis of laboratory parameters, differences between time points and superin-
fection status were tested using linear mixed effects models. To estimate the effect of superinfections on ventilator-free days (VFDs)
at 28 days (proportion of participants alive and off invasive mechanical ventilation at study day 28), we used a competing risk regres-
sionmodel according to Fine &Gray censored at 28 days, with the event of extubation as outcome event and death as the competing
risk. An alpha level of 0.05 was considered statistically significant. Statistical analysis was performed using STATA version 15
(StataCorp, College Station, TX), R version 3.6.3 (http://www.r-project.org/), SPSS Version 23 (SPSS Science, Chicago, IL, USA)
and Graphpad Prism 7 (San Diego, CA, USA).e2 Cell Reports Medicine 2, 100229, April 20, 2021
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This study has been registered at clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT04410263, https://clinicaltrials.gov/ct2/show/
NCT04410263). We followed the STROBE statement checklist in reports of cohort studies (https://www.strobe-statement.org/
index.php?id=available-checklists).Cell Reports Medicine 2, 100229, April 20, 2021 e3
